ReviewExpert opinion on drug delivery2010
Delivery of celecoxib for treating diseases of the eye: influence of pigment and diabetes.
Review in Expert opinion on drug delivery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Innovative formulations for the ocular delivery of coenzyme Q10.Drug delivery and translational research · 2025Article
- Celecoxib/Cyclodextrin Eye Drop Microsuspensions: Evaluation of In Vitro Cytotoxicity and Anti-VEGF Efficacy for Retinal Diseases.Pharmaceutics · 2023Article
- Non-Invasive Iontophoretic Delivery of Cytochrome c to the Posterior Segment and Determination of Its Ocular Biodistribution.Pharmaceutics · 2022Article
- Cyclodextrin Multicomponent Complexes: Pharmaceutical Applications.Pharmaceutics · 2021Review
- Epidemiology of Ocular Manifestations in Autoimmune Disease.Frontiers in immunology · 2021Review
- The MAPK signaling pathway mediates the GPR91-dependent release of VEGF from RGC-5 cells.International journal of molecular medicine · 2015Article
- Effect of formulation variables on preparation of celecoxib loaded polylactide-co-glycolide nanoparticles.PloS one · 2014Article
- Pigmented-MDCK (P-MDCK) cell line with tunable melanin expression: an in vitro model for the outer blood-retinal barrier.Molecular pharmaceutics · 2012Article
- Intraocular distribution of melanin in human, monkey, rabbit, minipig and dog eyes.Experimental eye research · 2012Article
- Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib.Molecular pharmaceutics · 2012Article
- Pazopanib, a multitargeted tyrosine kinase inhibitor, reduces diabetic retinal vascular leukostasis and leakage.Microvascular research · 2011Article
- Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23~27~24 clusters.Proceedings of the National Academy of Sciences of the United States of America · 2011Article
- Recent advances in ophthalmic drug delivery.Therapeutic delivery · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
importance of the fieldAge-related macular degeneration (AMD) and diabetic retinopathy (DR) are two major causes of blindness. In these disorders, growth factors such as vascular endothelial growth factor (VEGF) are upregulated, leading to either enhanced vascular permeability or proliferation of endothelium. While corticosteroid therapies available at present suffer from side effects including cataracts and elevated intraocular pressure, anti-VEGF antibody therapies require frequent intravitreal injections, a procedure that can potentially lead to retinal detachment or endophthalmitis. Thus, there is a need to develop safe, sustained release therapeutic approaches for treating AMD and DR. AREAS COVERED IN THIS REVIEW: This review discusses the pharmacological basis for using celecoxib, an anti-inflammatory drug capable of selectively inhibiting cycloxygenase 2, in treating AMD and DR. In addition, this article discusses the safety, delivery advantage and efficacy of celecoxib by transscleral retinal delivery, a periocular delivery approach that is less invasive to the globe compared with intravitreal injections. WHAT THE READER WILL GAIN: The reader will gain insights into the development of a pharmacological agent and a sustained release delivery system for treating DR and AMD. Further, the reader will gain insights into the influence of eye physiology including pigmentation and disease states such as DR on retinal drug delivery. TAKE HOME MESSAGE: Transscleral sustained delivery of anti-inflammatory agents is a viable option for treating retinal disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.